Supra-additive cytotoxic effects of a combination of cytostatic drugs and antibody-induced complement activation on tumor cells in vitro

Tumor Biology

Volumn 22, Issue 2, 2001, Pages 97-103

  Brezicka, Thomas ^a,b   Einbeigi, Zakaria ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemotherapy; Complement mediated cytotoxicity; Gangliosides; Monoclonal antibody; Neoplasm

Indexed keywords

CISPLATIN; CYTOSTATIC AGENT; DOXORUBICIN; ETOPOSIDE; MONOCLONAL ANTIBODY;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOTOXICITY; DISSEMINATED CANCER; HUMAN; HUMAN CELL; HYPOTHESIS; LUNG SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR CELL CULTURE;

EID: 0035178569     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050603     Document Type: Article

References (32)

1. Testicular cancer, review
2. Future directions in the management of small cell lung cancer
3. Continuous cultures of fused cells secreting antibody of predicted specificity
4. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
5. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
6. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
7. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
8. Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: Emerging concepts of a tumour-targeted strategy
9. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
10. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
11. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma
12. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
13. Signaling antibodies in cancer therapy
14. Reactivity of monoclonal antibody FC-2.15 against drug-resistant breast cancer cells. Additive cytotoxicity of Adriamycin and Taxol with FC-2.15
15. Binding specificity of monoclonal antibodies to ganglioside Fuc-GM1
16. Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1
17. Fucosyl-GM1 - A ganglioside associated with small cell lung carcinoma
18. Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies
19. Immunohistochemical detection of two small cell lung carcinoma-associated antigens defined by MAbs F12 and 123C3 in bronchoscopy biopsy tissues
20. Tumor-cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small-cell lung carcinoma
21. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
22. Chemosensitivity and radiosensitivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid assay
23. Chemosensitivity testing of small cell lung cancer using the MTT assay
24. Synergistic interaction of anticancer agents: A cellular perspective
25. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies
26. Complement depletion in vitro limits monoclonal antibody 6-19-dependent complement-mediated killing of tumor cells in bone marrow
27. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a
28. The membrane attack pathway of complement
29. Ultrastructural and spectroscopic methods in the study of anthracycline-membrane interaction
30. Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: Clinical and biologic effects
31. Anti-tumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
32. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers